{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:34:00Z","timestamp":1769276040136,"version":"3.49.0"},"reference-count":31,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2015]]},"DOI":"10.5551\/jat.27425","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T22:07:06Z","timestamp":1425593226000},"page":"676-684","source":"Crossref","is-referenced-by-count":13,"title":["Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes"],"prefix":"10.5551","volume":"22","author":[{"given":"Takahisa","family":"Hirose","sequence":"first","affiliation":[{"name":"Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Teikyo Academic Research Center, Teikyo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Abe","sequence":"additional","affiliation":[{"name":"Pharmacovigilance & Post-marketing Surveillance, KISSEI Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Taneyama","sequence":"additional","affiliation":[{"name":"Pharmacovigilance & Post-marketing Surveillance, KISSEI Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"J-BENEFIT study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Py\u00f6r\u00e4l\u00e4 K: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulindependent diabetic and nondiabetic subjects. Circulation, 1990; 82: 27-36","DOI":"10.1161\/01.CIR.82.1.27"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Teramoto T, Shirai K, Daida H, Yamada N: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol, 2012; 11: 29","DOI":"10.1186\/1475-2840-11-29"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ohno Y, Miyoshi T, Noda Y, Oe H, Toh N, Nakamura K, Kohno K, Morita H, Ito H: Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol, 2014; 13: 71","DOI":"10.1186\/1475-2840-13-71"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Klempfner R, Goldenberg I, Fisman EZ, Matetzky S, Amit U, Shemesh J, Tenenbaum A: Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome. Am J Cardiol, 2014; 113: 12-16","DOI":"10.1016\/j.amjcard.2013.08.033"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, Klempfner R, Shemesh J, Goldenberg I: Cardiovascular events in patients received combined fibrate\/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One, 2012; 7: e35298","DOI":"10.1371\/journal.pone.0035298"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Teramoto T, Abe K, Taneyama T: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Cardiovasc Diabetol, 2013; 12: 163","DOI":"10.1186\/1475-2840-12-163"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A: Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother, 2011; 45: 1230-1239","DOI":"10.1345\/aph.1Q110"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ikewaki K, Noma K, Tohyama J, Kido T, Mochizuki S: Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study. Int J Cardiol, 2005; 101: 441-447","DOI":"10.1016\/j.ijcard.2004.03.071"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Khan HA, Sobki SH, Khan SA: Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med, 2007; 7: 24-29","DOI":"10.1007\/s10238-007-0121-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhang L, Qiao Q, Tuomilehto J, Hammar N, Janus ED, S\u00f6derberg S, Mohan V, Ramachandran A, Dong YH, Lam TH, Pang ZC: Blood lipid levels in relation to glucose status in seven populations of Asian origin without a prior history of diabetes: the DECODA study. Diabetes Metab Res Rev, 2009; 25: 549-557","DOI":"10.1002\/dmrr.994"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PW: Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care, 2002; 25: 989-994","DOI":"10.2337\/diacare.25.6.989"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, Yoshino G: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol, 2004; 24: 558-563","DOI":"10.1161\/01.ATV.0000117179.92263.08"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hirano T, Kazumi T, Yoshino G: Long-term efficacy of bezafibrate in reduction of small, dense low-density lipoprotein by hypotriglyceridemic action. Curr Ther Res Clin Exp, 2000; 61: 127-136","DOI":"10.1016\/S0011-393X(00)80010-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 2001; 161: 1413-1419","DOI":"10.1001\/archinte.161.11.1413"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation, 2005; 112: 3375-3383","DOI":"10.1161\/CIRCULATIONAHA.104.532499"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kitamura A, Noda H, Nakamura M, Kiyama M, Okada T, Imano H, Ohira T, Sato S, Yamagishi K, Iso H: Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb, 2011; 18: 454-463","DOI":"10.5551\/jat.7237"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab, 2011; 96: 3448-3456","DOI":"10.1210\/jc.2011-0622"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D: Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol, 2008; 52: 1769-1781","DOI":"10.1016\/j.jacc.2008.08.039"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Brugts JJ, Yetgin T, Hoeks SE, Gotto Am, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ, 2009; 338: b2376","DOI":"10.1136\/bmj.b2376"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 2008; 371: 117-125","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Saito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, Fox JC: Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis, 2007; 194: 505-511","DOI":"10.1016\/j.atherosclerosis.2006.11.028"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J: Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). Cardiovasc Res, 2001; 52: 290-298","DOI":"10.1016\/S0008-6363(01)00382-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) G\u00f3mez-Gerique JA, Ros E, Oliv\u00e1n J, Mostaza JM, Vilardell M, Pint\u00f3 X, Civeira F, Hern\u00e1ndez A, da Silva PM, Rodriguez-Botaro A, Zamb\u00f3n D, Lima J, D\u00edaz C, Aristegui R, Sol JM, Chaves J, Hern\u00e1ndez G; ATOMIX Investigators: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis, 2002; 162: 245-251","DOI":"10.1016\/S0021-9150(01)00708-0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nagai T, Tomizawa T, Nakajima K, Mori M: Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb, 2000; 7: 91-96","DOI":"10.5551\/jat1994.7.91"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Sano K, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, Saito Y, Yano T, Watanabe K, Watanabe Y, Mishina H, Obata JE, Kawabata K, Kugiyama K: Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J, 2010; 74: 1644-1650","DOI":"10.1253\/circj.CJ-10-0079"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Kita T: Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb, 2005; 12: 98-106","DOI":"10.5551\/jat.12.98"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T: Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation, 2002; 106: 1771-1776","DOI":"10.1161\/01.CIR.0000032261.12632.D7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Sone H, Tanaka S, Tanaka S, Iimuro S, Ishibashi S, Oikawa S, Shimano H, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group: Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: Subanalysis of the Japan Diabetes Complications Study. Diabetes Care, 2012; 35: 1150-1157","DOI":"10.2337\/dc11-1412"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/22\/7\/22_27425\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T15:17:07Z","timestamp":1598800627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/22\/7\/22_27425\/_article"}},"subtitle":["A Subgroup Analysis of the J-BENEFIT Study"],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.27425","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}